Clinical Trial News and Research

RSS

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Hot flashes. Night sweats. These are the most common - or at least the most commonly talked about - symptoms of menopause. But one reality of The Change for many women is less discussed yet no less important: problems with vaginal health and sexual function.

6 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Higher insulin levels linked to worse prognosis in advanced breast cancer

Patients with breast cancer that has spread to other parts of the body (metastasised) and who have higher insulin levels than normal, but are not diabetic, have a significantly worse prognosis compared with those with normal insulin levels, a researcher will tell the Advanced Breast Cancer Third International Consensus Conference tomorrow (Friday).

5 Nov 2015

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.

5 Nov 2015

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.

5 Nov 2015

New vaccine candidate shows great promise at fighting respiratory syncytial virus

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.

5 Nov 2015

Study suggests need for specific treatment options for adolescents with onset type 2 diabetes

New results from the Treatment Options for Type 2 Diabetes in Youth study (TODAY) examined predictors of the outcomes in youth with onset type 2 diabetes (T2D) based on early characteristics at diagnosis, and suggests the need for specific criteria for adolescents that are different from those in adults.

5 Nov 2015

Article explores viewpoints on role of mild cognitive impairment in Parkinson's disease

The current issue of Neurodegenerative Disease Management explores evolving viewpoints on the role of mild cognitive impairment in Parkinson's Disease (PD-MCI), a medical issue which currently lacks consensus. Neurodegenerative Disease Management is published by Future Science Group. The article is also available free of charge to members of Neurology Central, FSG's online community for the international neurology community.

5 Nov 2015

Children's Cancer Institute licenses Labmatrix to support 'Zero Childhood Cancer' program

BioFortis today announced that Children's Cancer Institute has licensed Labmatrix, the award-winning precision medicine and biobanking software platform, to support their "Zero Childhood Cancer" program.

4 Nov 2015

Cerapedics' i-FACTOR Peptide Enhanced Bone Graft gets FDA approval for use in cervical spine surgery

Cerapedics, a privately-held orthobiologics company, announced today the U.S. Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) application for i-FACTOR™ Peptide Enhanced Bone Graft for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. i-FACTOR bone graft is the first bone graft to be approved for use in the cervical spine and only the second PMA-approved bone graft in the spine.

4 Nov 2015

OncoSec signs definitive agreements to purchase $7.5 million of securities in registered direct offering

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.5 million of securities in a registered direct offering.

4 Nov 2015

Study explores benefits of breast cancer adjuvant therapies

After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy and endocrine drugs to reduce the risk of the cancer returning. It's been assumed that the treatment effects of these therapies remain constant over time, but a new study from the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio suggests the opposite is true.

4 Nov 2015

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Pancreas cancer remains one of the deadliest cancers worldwide. In the United States, it accounts for only three percent of all diagnosed cancers but it causes almost seven percent of all cancer deaths. A pancreas cancer diagnosis often comes after age 50 and after the cancer has spread, making it difficult to remove surgically.

4 Nov 2015

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug) for potential disease modifying treatment of osteoarthritis (OA) of the knee at 2015 American College of Rheumatology Annual Meeting.

4 Nov 2015

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment.

4 Nov 2015

Approval to start trial of Videregen's replacement trachea technology

The INSPIRE consortium, led by Videregen Ltd, has received approval from the MHRA1 to start a UK clinical trial with its tissue engineered replacement trachea.

3 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

New combination treatment provides better wound healing compared to SSGs alone

The use of meshed split skin autographs (SSGs) is a standard treatment for large, deep burns. However, serious scarring is often a result. In an effort to improve wound healing and reduce scarring, a team of researchers in The Netherlands tested a treatment technique on patients with serious, deep burns that employed SSGs along with autologous cultured proliferating epidermal cells (ECs) compared to SSGs alone.

3 Nov 2015

Clinical Trial News and Research

Hutchison MediPharma begins sulfatinib Phase I trial in US

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

Higher insulin levels linked to worse prognosis in advanced breast cancer

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

New vaccine candidate shows great promise at fighting respiratory syncytial virus

Study suggests need for specific treatment options for adolescents with onset type 2 diabetes

Article explores viewpoints on role of mild cognitive impairment in Parkinson's disease

Children's Cancer Institute licenses Labmatrix to support 'Zero Childhood Cancer' program

Cerapedics' i-FACTOR Peptide Enhanced Bone Graft gets FDA approval for use in cervical spine surgery

OncoSec signs definitive agreements to purchase $7.5 million of securities in registered direct offering

Study explores benefits of breast cancer adjuvant therapies

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

Approval to start trial of Videregen's replacement trachea technology

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

New combination treatment provides better wound healing compared to SSGs alone

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer